Search research articles
Contact Us
Filters
Showing results (41-50 of 79) with videos related to
Page
of 8
Sort By:
British Journal of Cancer
|
June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
C Pezaro, D Mukherji, N Tunariu, et al.
Clinical Radiology
|
January 4, 2015
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
C Pezaro, A Omlin, R Perez-Lopez, et al.
Prostate Cancer and Prostatic Diseases
|
October 2, 2013
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
O B Goodman, T W Flaig, A Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2000
Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide
J S de Bono, A G Dalgleish, J Carmichael, et al.
British Journal of Cancer
|
November 12, 2015
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
E Geuna, D Roda, S Rafii, et al.
British Journal of Cancer
|
March 5, 2002
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer
T R J Evans, K W Colston, F J Lofts, et al.
British Journal of Cancer
|
July 1, 2010
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
U Lassen, L R Molife, M Sorensen, et al.
British Journal of Cancer
|
June 10, 2004
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
D Bissett, J Cassidy, J S de Bono, et al.
British Journal of Cancer
|
August 10, 2013
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
A Omlin, C J Pezaro, S Zaidi, et al.
Oncology
|
August 15, 2012
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials
B Basu, J Vitfell-Pedersen, V Moreno Garcia, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 79) with videos related to
Sort By:
Page
of 8
British Journal of Cancer
|
June 29, 2013
Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer
C Pezaro, D Mukherji, N Tunariu, et al.
Clinical Radiology
|
January 4, 2015
Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer
C Pezaro, A Omlin, R Perez-Lopez, et al.
Prostate Cancer and Prostatic Diseases
|
October 2, 2013
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer
O B Goodman, T W Flaig, A Molina, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 26, 2000
Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide
J S de Bono, A G Dalgleish, J Carmichael, et al.
British Journal of Cancer
|
November 12, 2015
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
E Geuna, D Roda, S Rafii, et al.
British Journal of Cancer
|
March 5, 2002
A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer
T R J Evans, K W Colston, F J Lofts, et al.
British Journal of Cancer
|
July 1, 2010
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours
U Lassen, L R Molife, M Sorensen, et al.
British Journal of Cancer
|
June 10, 2004
Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT)
D Bissett, J Cassidy, J S de Bono, et al.
British Journal of Cancer
|
August 10, 2013
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer
A Omlin, C J Pezaro, S Zaidi, et al.
Oncology
|
August 15, 2012
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trials
B Basu, J Vitfell-Pedersen, V Moreno Garcia, et al.
Page
of 8